Viron Therapeutics, Inc. has signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing for its lead product candidate, VT-111, currently in Phase II trials for the treatment of inflammation associated with Acute Coronary Syndrome (ACS). “We are very pleased to be working with Viron,” said Frank Tielens, president of Diosynth Biotechnology. “Our experience in technology transfer, in process development and in cGMP producti...